










Abstract：Recentlyit has been reported that arsenic trioxide（As203）is very
effectiveinthetreatmentofacutepromyelocyticleukemia（APL）byinducingapoptosis，
but the molecular mechanism ofits action on otherleukemia remains unclear．In the
presentstudy，WeteStedtheeffectofAs203atlowconcentrationO．2572・OFLMonK562，a
chronic myelogenousleukemia cellline．As203inhibited the cellgrowth of K562in a




bc1－2expression was not changed・Treatment of the cells with antトCD95monoclonal
antibody or ZVAD－fmk capable of blocking the CD95signaling pathway ameliorated
As203－induced oncosis．These results suggest that theinduction of oncosis by As203
invoIves CD95／CD95L pathwayin K562and As203may prOVide a novel therapy for















Celldeathis not only an essentialphenomenonin normaldevelopment，but also plays a
CruCialroleincancerchemotherapyll）．Theendstateofcellulartoxicityfallsintoatleasttwo
distinctcelldeathpathways：apOptOSisandoncosis，bothofwhichprogressintoirreversible
necrosis．Apoptosisis characterized by cellular shrinkage，Chromatin condensation，and
apoptotic bodies．On the other hand，OnCOSisis described as cellular swelling，Organelle
SWelling，blebbing，andincreased membrane permeability．Necrosis can occur after both






Japanese Cancer Research Resources Bank．We also used two humanleukemia／lymphoma
celllines：HL－60，aCutemyeloidleukemia（theFrench－American－Britishclassification，M2）
celllineandRL，t（14；18）B－Celllymphomacelllineoverexpressingbc1－2ascontrol．They
were culturedin RPMI1640medium supplemented withlOO U／ml penicillin，100pg／ml









MTT solution was added to200iLlof the cellsuspenSionsin a96multiJWell dish，and
incubatedat37℃for2hours．Thedishwascentrifugedat400gfor5minutes，themedium
wasdiscarded，and200FLlofDMSO（dimethylsulfoxide）wasaddedtoeachwelltodissoIve
MTT formaZanS．Finally，Opticaldensities（OD）at550－650nm were measured with an
ELISAscan（SLT－LabinstrumentS，Austria）．
4．MorphologiCalassessment











The changes of CD95，CD95L and bc1－2expressions by As203Were aSSeSSed withFCM．
After treatmentwithorwithout1．0－2．OiLMAs203for1－4days，105cellswerewashed twice
With cold PBS andincubatedwith5．O plofFITC－COnjugated anti－human CD95monoclonal
antibody（MoAb）（MBL，Japan）orFITCLCOnjugatedanti－humanCD95LMoAb（Fujisawa，
Japan）at4℃inthedarkfor30minutes．Forthedetectionofbc1－2proteinexpression15），HL－
60and RL were used as positive controIs．5×106cells were resuspendedin2ml of2％
paraformaldehyde．Afterincubation forlO minutes onice，100fLl of1％Triton XlOO was











to each well andincubated at37℃for2hours．Finally，Samples were examined by the
fluorometer with a385nm excitation filter and a538nm emission filter．
8．BlockingoftheCD95／CD95LpathwaybyantiJ：D95MoAbandZVAI”mk
Anti－CD95MoAb（MBL，Japan）OrcaspasefamilyinhibitorZVAD－fmk（MBL，Japan）













inhibitory effects were weak atlower concentrations（0．25－0・5FLM），As203inhibited






were observedin HL－60and RL（Fig．2A）．Toinvestigate whether theinhibition of cell
growthisduetocellcyclearrest，WeeXaminedcellcyclebyFCM・AsshowninFig2B，Cell
cycle arrested at G2＋M phasesin K562Compared with apoptotic changes of cellcycle
arrested at subGlin HL－60and RL．
3．ChangeSinCD95／CD95Landbc1－2expression





























Fig．2A．Changes of morphology and cell cyclein HL－60，RL and K562by As203．Apoptotic changes of
morphology（arrOW）andcellcycleinHL－60andRLwereshownaSpOSitivecontrol．Oncoticchanges






























































Fig．3．Upregulation ofCD95／CD95L expression by
As203．After K562cultured withor without






































































Fig．4．Downregulation of bc1－2　expression by
As203．HLT60　and RL were employed as





























was confirmed by cellular swelling，SWelling of organelles，blebbing of cytoplasm，nO
significant Changesin nucleus，and cell cycle arrested at G2＋M phases・These results
confimedthatthecellgrowthinhibitioninK562isduetooncosis．
The CD95／CD95L pathwayinvoIves expression of transmembrane receptor CD95and
CD95L．CD95activates the Fas－aSSOCiated death domain（FADD）protein to cleave pro－
caspase8tocaspase8，thencaspase8cleavesproTCaSpaSe3tocaspase3whichisthefinal
step of celldeath18r2O）．It was reported that CD95／CD95L plays a novelrolein anticancer
drugs21－23）・In this study，the expression ofCD95and CD95L on K562were upregulated by
As203inl day．Furthermore，As203treatment OfK562for2days activated both caspase8
andcaspase3．ThesefindingssuggestthattheCD95／CD95Lpathwayplaysamajorrolein
theAs20rinducedoncosisinK562．TofurtherdeterminewhetherAs203inducesoncosisonly
via the CD95／CD95L pathway，anti－CD95MoAb or ZVAD－fmk was used to block the




as a central rolein As203－induced cell death，throughoutthe release of cytochrome c24），
activating downstream caspases25），and downregulation of bcト2　expressionl・6，10）・In our
previous study26），bc1－2expression was downregulated by As203in positive control，HL－60
and RL．However，nO detectable change of bc1－2expression was foundin K562．This
discrepancy may be due to the possibility that bcト2directly orindirectly determines cell






























































FADDThomologousICE／CEDT3－1ike protease，is recruited to the CD95（Fas／AP0－1）death－inducing
Slgnalingcomplex．Ce1185：817－827，1996．
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